
Gyre Therapeutics Inc GYRE.OQ GYRE.O is expected to report resultson May 7 (estimated) for the period ending March 31 2025
The San Diego California-based company is expected to report revenue of $28.4 million, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Gyre Therapeutics Inc is for earnings of 3 cents per share.
The one available analyst rating on the shares is "buy".
The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
Wall Street's median 12-month price target for Gyre Therapeutics Inc is $20.00, above its last closing price of $9.26.
This summary was machine generated May 5 at 11:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)